Compounds > n-(2'-(dimethylamino)ethyl)acridine-4-carboxamide
Page last updated: 2024-12-07

n-(2'-(dimethylamino)ethyl)acridine-4-carboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID107805
CHEMBL ID9940
SCHEMBL ID105276
MeSH IDM0162715

Synonyms (33)

Synonym
brn 6066471
4-acridinecarboxamide, n-(2-(dimethylamino)ethyl)-
n-(2-(dimehtylamino)ehtyl)acridine-4-carboxamide
daca
n-(2-(dimethylamino)ethyl)acridine-4-carboxamide
ccris 4457
nsc 601316
n-(2-(dimethylamino)ethyl)-4-acridinecarboxamide
nsc-601316
acridine carboxamide
sn 22995
daca-n
n-(2'-(dimethylamino)ethyl)acridine-4-carboxamide
89459-25-6
CHEMBL9940
unii-0n3v8r4e13
0n3v8r4e13 ,
SCHEMBL105276
n-[2-(dimethylamino)ethyl]acridine-4-carboxamide
XBGNERSKEKDZDS-UHFFFAOYSA-N
nsc 601316 [who-dd]
xr-5000
AKOS028110743
DTXSID60237739
4-acridinecarboxamide, n-[2-(dimethylamino)ethyl]-
AS-68353
D93759
DB11880
Q4675115
n-[2-(dimethylamino)ethyl]-4-acridinecarboxamide
n-[2-(dimethylamino)ethyl]acridine-4-carboxamide,
nsc754367
nsc-754367

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The 121-mumol/kg dose was well tolerated by mice, with sedation being the only obvious side effect and no significant alterations in blood biochemistry or haematological parameters being recorded."( Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse.
Cornford, EM; Evans, SM; Kestell, P; Paxton, JW; Robertson, IG; Young, D, 1992)		0.28

Pharmacokinetics

ExcerptReferenceRelevance
" studies, but the shape of the plasma concentration-time profile was considerably different, reflecting a 3-fold lower Cmax value (20."( Intraperitoneal administration of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in the mouse: bioavailability, pharmacokinetics and toxicity after a single dose.
Evans, SM; Paxton, JW; Robertson, IG; Young, D, 1992)		0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (78)

Assay IDTitleYearJournalArticle
AID227091Ratio of inhibitory concentration of Human Jurkat leukemia D (JLD) and Human Jurkat leukemia C (JLC)1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors.
AID91916Inhibitory concentration against Human Jurkat leukemia (JLC) cell proliferation1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors.
AID55127Binding constant for DNA by ethidium displacement1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
Potential antitumor agents. 54. Chromophore requirements for in vivo antitumor activity among the general class of linear tricyclic carboxamides.
AID98488Concentration required to inhibit growth of murine leukemia (L1210) cells in culture1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
Potential antitumor agents. 54. Chromophore requirements for in vivo antitumor activity among the general class of linear tricyclic carboxamides.
AID55802Antiproliferative activity against human DU145 prostate cell line1999Bioorganic & medicinal chemistry letters, Sep-06, Volume: 9, Issue:17
BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II.
AID1215672Drug metabolism in pooled human hepatocytes assessed as aldehyde oxidase-mediated drug metabolism at 10 uM up to 120 mins by HPLC analysis in presence of 50 uM of hydralazine2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.
AID365819Cytotoxicity against human fibroblast cells by Hoechst test2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.
AID162408Binding constant to Poly (dA-dT) determined by ethidium bromide displacement2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Kinetic studies of the binding of acridinecarboxamide topoisomerase poisons to DNA: implications for mode of binding of ligands with uncharged chromophores.
AID227090Ratio of inhibitory concentration of Human Jurkat leukemia A (JLA) and Human Jurkat leukemia C (JLC)1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors.
AID25047Lipophilicity expressed as the negative logarithm of the equilibrium constant2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Kinetic studies of the binding of acridinecarboxamide topoisomerase poisons to DNA: implications for mode of binding of ligands with uncharged chromophores.
AID54657Displacement of ethidium from poly(dA/T) or poly(dG/C)-DNA1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Potential antitumor agents. 56. "Minimal" DNA-intercalating ligands as antitumor drugs: phenylquinoline-8-carboxamides.
AID84458The compound was tested for cytotoxic activity against HT-29 cell line(human colon adeno carcinoma)2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
N4-(omega-Aminoalkyl)-1-[(omega-aminoalkyl)amino]-4- acridinecarboxamides: novel, potent, cytotoxic, and DNA-binding agents.
AID98543Inhibition of L1210 cell growth by 50%2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Kinetic studies of the binding of acridinecarboxamide topoisomerase poisons to DNA: implications for mode of binding of ligands with uncharged chromophores.
AID55297Inhibitory concentration against ethidium bromide binding to [poly(dA-dT)] [poly(dA-dT)]1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Electron-deficient DNA-intercalating agents as antitumor drugs: aza analogues of the experimental clinical agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
AID153339Growth inhibitory activity against murine P388 leukemia cells2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
AID1915525Antiproliferative activity against human PC-3 cells incubated for 48 hrs by Sulforhodamine B staining method2021European journal of medicinal chemistry, Jan-01, Volume: 209Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID133618Optimal dose administered intraperitoneally on days 5,9 and 13 after intravenous inoculation of lewis lung carcinoma cells.1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Potential antitumor agents. 56. "Minimal" DNA-intercalating ligands as antitumor drugs: phenylquinoline-8-carboxamides.
AID162548Binding constant to Poly (dG-dC) determined by ethidium bromide displacement2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Kinetic studies of the binding of acridinecarboxamide topoisomerase poisons to DNA: implications for mode of binding of ligands with uncharged chromophores.
AID54637Binding affinity against CT-DNA from calf thymus DNA2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
N4-(omega-Aminoalkyl)-1-[(omega-aminoalkyl)amino]-4- acridinecarboxamides: novel, potent, cytotoxic, and DNA-binding agents.
AID365813Cytotoxicity against human Jurkat cells by resazurin reduction test2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.
AID1215671Drug metabolism in pooled human hepatocytes assessed as aldehyde oxidase-mediated drug metabolism at 10 uM up to 120 mins by HPLC analysis in presence of 25 uM of hydralazine2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.
AID132732Percent increase in life span of compound-treated mice bearing P388 leukemia2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Kinetic studies of the binding of acridinecarboxamide topoisomerase poisons to DNA: implications for mode of binding of ligands with uncharged chromophores.
AID95291Concentration required to inhibit 50% growth of human Jurkat cells1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
AID10186The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma )2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
N4-(omega-Aminoalkyl)-1-[(omega-aminoalkyl)amino]-4- acridinecarboxamides: novel, potent, cytotoxic, and DNA-binding agents.
AID47517The compound was tested for cytotoxic activity against CH1 cell line(human ovarian carcinoma )2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
N4-(omega-Aminoalkyl)-1-[(omega-aminoalkyl)amino]-4- acridinecarboxamides: novel, potent, cytotoxic, and DNA-binding agents.
AID110785Number of mice(with Colon 38 tumors) cured after treatment of 200 mg/kg/day dose given as 2 times in a day for 7 days out of 5 mice2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
AID98128Compound concentration that reduces cell growth of L1210 leukemia cultures to 50% of controls after 70h.1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Potential antitumor agents. 56. "Minimal" DNA-intercalating ligands as antitumor drugs: phenylquinoline-8-carboxamides.
AID365810Cytotoxicity against human M4Beu cells by resazurin reduction test2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.
AID225917Tested for binding affinity against AT from [poly(dA-dT)]2.2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
N4-(omega-Aminoalkyl)-1-[(omega-aminoalkyl)amino]-4- acridinecarboxamides: novel, potent, cytotoxic, and DNA-binding agents.
AID365812Cytotoxicity against human DLD1 cells by resazurin reduction test2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.
AID234397Ratio of inhibitory activity against doxorubicin resistant jurkat cells to inhibitory activity against wild type human jurkat cells1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
AID100240Inhibitory concentration required to reduce Lewis lung carcinoma cell number to 50% of control cultures1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
AID229289Ratio of IC50 of Jurkat leukemia amsacrine (JLA) to the IC50 of Jurkat leukemia (JLC sensitive, wild type)1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
AID21285Compound was evaluated for ionizable constant, pKa1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
Potential antitumor agents. 54. Chromophore requirements for in vivo antitumor activity among the general class of linear tricyclic carboxamides.
AID365816Cytotoxicity against mouse B16F0 cells by Hoechst test2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.
AID84434Antiproliferative activity against human HT-29 colon cell line1999Bioorganic & medicinal chemistry letters, Sep-06, Volume: 9, Issue:17
BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II.
AID119957Optimal dose administered intraperitoneally after intraperitoneal inoculation of 10 e 6 P388 leukemia cells1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
Potential antitumor agents. 54. Chromophore requirements for in vivo antitumor activity among the general class of linear tricyclic carboxamides.
AID55643Binding constant to poly[d(AT)] by ethidium bromide displacement1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of "minimal" DNA-intercalating agents which may not act via topoisomerase II.
AID10189The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma )2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
N4-(omega-Aminoalkyl)-1-[(omega-aminoalkyl)amino]-4- acridinecarboxamides: novel, potent, cytotoxic, and DNA-binding agents.
AID232175Ratio of growth inhibitory activity against human Jurkat leukemia cell line (JLD- resistant to doxorubicin) to that of Jurkat leukemia cell line2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
AID119959Optimal dose administered intraperitoneally to Lewis lung carcinoma cells1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
Potential antitumor agents. 54. Chromophore requirements for in vivo antitumor activity among the general class of linear tricyclic carboxamides.
AID365814Cytotoxicity against mouse B16F0 cells by resazurin reduction test2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.
AID365811Cytotoxicity against human fibroblast cells by resazurin reduction test2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.
AID150522In vitro cell growth inhibitory activity against wild type P388 murine leukemia cell line (P388/W)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of "minimal" DNA-intercalating agents which may not act via topoisomerase II.
AID114250In vivo antitumor activity against subcutaneous Colon 38 tumors in mice determined as delay in growth after 200 mg/kg/day dose given as 2 times in a day for 7 days2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
AID229325Ratio of IC50 of mutant Jurkat leukemia (JLD) to the IC50 of Jurkat leukemia (JLC sensitive, wild type)1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
AID47519The compound was tested for cytotoxic activity against CH1/Cs cell line(human ovarian carcinoma)2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
N4-(omega-Aminoalkyl)-1-[(omega-aminoalkyl)amino]-4- acridinecarboxamides: novel, potent, cytotoxic, and DNA-binding agents.
AID1915526Antiproliferative activity against human DU-145 cells incubated for 48 hrs by Sulforhodamine B staining method2021European journal of medicinal chemistry, Jan-01, Volume: 209Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID150523In vitro cell growth inhibitory activity against amsacrine-resistant P388 cell line (P388/A)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of "minimal" DNA-intercalating agents which may not act via topoisomerase II.
AID232174Ratio of growth inhibitory activity against human Jurkat leukemia cell line (JLA- resistant to amsacrine) to that of Jurkat leukemia cell line2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
AID95455Growth inhibitory activity against human Jurkat leukemia cell line (JLC)2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
AID150670Inhibitory concentration to reduce cell number to 50% of Murine P388 leukemia cell culture1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors.
AID150673Inhibitory concentration required to reduce murine p388 leukemia cell number to 50% of control cultures1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
AID234396Ratio of inhibitory activity against amsacrine resistant jurkat cells to inhibitory activity against wild type human jurkat cells1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
AID100239Inhibitory concentration against Murine Lewis lung carcinoma (LLC) cell proliferation1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors.
AID91917Inhibitory concentration required to reduce human Jurkat leukemia (JLC sensitive, wild type) cell number to 50% of control cultures1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
AID115368Percentage increase in lifespan of P388 tumor cell bearing animal compared to nontreated tumor bearing controls at given optimal dose1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
Potential antitumor agents. 54. Chromophore requirements for in vivo antitumor activity among the general class of linear tricyclic carboxamides.
AID103294Growth inhibitory activity against murine Lewis lung carcinoma cell line2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
AID25629Ionization constant of chromophore measured by UV spectroscopy in 20% dimethylformamide.1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Potential antitumor agents. 56. "Minimal" DNA-intercalating ligands as antitumor drugs: phenylquinoline-8-carboxamides.
AID387557Cytotoxicity against human HT-29 cells after 144 hrs2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs.
AID115370Percentage increase in lifespan of P388 tumor cell bearing animal compared to nontreated tumor bearing controls at given optimal dose; Not active1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
Potential antitumor agents. 54. Chromophore requirements for in vivo antitumor activity among the general class of linear tricyclic carboxamides.
AID225928Binding affinity against GC from [poly(dG-dC)]2.2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
N4-(omega-Aminoalkyl)-1-[(omega-aminoalkyl)amino]-4- acridinecarboxamides: novel, potent, cytotoxic, and DNA-binding agents.
AID133617Optimal dose administered intraperitoneally on days 1,5 and 9 after intraperitoneal inoculation of P388 leukemia cells.1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Potential antitumor agents. 56. "Minimal" DNA-intercalating ligands as antitumor drugs: phenylquinoline-8-carboxamides.
AID103441Antiproliferative activity against human MCF-7 breast cell line1999Bioorganic & medicinal chemistry letters, Sep-06, Volume: 9, Issue:17
BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II.
AID115365% increase in lifespan of Lewis lung carcinoma tumor cell bearing animal compared to nontreated tumor bearing controls at given optimal dose1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
Potential antitumor agents. 54. Chromophore requirements for in vivo antitumor activity among the general class of linear tricyclic carboxamides.
AID130322Percentage increase in lifespan of P388 tumor-bearing mice compared with tumor-bearing controls at optimal dose of 65 mg/kg/day1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Electron-deficient DNA-intercalating agents as antitumor drugs: aza analogues of the experimental clinical agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
AID103106Inhibitory activity of tested against Murine Lewis lung carcinoma1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
AID150500Inhibition of P388 leukemia cells growth in culture1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Electron-deficient DNA-intercalating agents as antitumor drugs: aza analogues of the experimental clinical agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
AID152987Ratio of IC50 value of P388/A and P388/W cell lines1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of "minimal" DNA-intercalating agents which may not act via topoisomerase II.
AID150664Inhibitory activity against Murine p38 leukemia1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
AID202842Antiproliferative activity against human SKOV-3 ovarian cell line1999Bioorganic & medicinal chemistry letters, Sep-06, Volume: 9, Issue:17
BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II.
AID131493In vivo increased lifespan in mice implanted intraperitoneally with wild type P388 murine leukemia cell line at the optimal dose of 66 mg/kg/day1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of "minimal" DNA-intercalating agents which may not act via topoisomerase II.
AID202979The compound was tested for cytotoxic activity against SKOV-3 cell line(human ovarian carcinoma )2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
N4-(omega-Aminoalkyl)-1-[(omega-aminoalkyl)amino]-4- acridinecarboxamides: novel, potent, cytotoxic, and DNA-binding agents.
AID132726Percent increase in life span of compound-treated mice bearing Lewis lung carcinoma2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Kinetic studies of the binding of acridinecarboxamide topoisomerase poisons to DNA: implications for mode of binding of ligands with uncharged chromophores.
AID365817Cytotoxicity against human DLD1 cells by Hoechst test2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.
AID365818Cytotoxicity against human Jurkat cells by Hoechst test2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.
AID365815Cytotoxicity against human M4Beu cells by Hoechst test2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.
AID130509Percentage increase in lifespan of treated animals(at the optimal dose) compared to controls. Average lifespan of control animals was 11 days (P388).1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Potential antitumor agents. 56. "Minimal" DNA-intercalating ligands as antitumor drugs: phenylquinoline-8-carboxamides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (63)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (6.35)18.7374
1990's44 (69.84)18.2507
2000's11 (17.46)29.6817
2010's3 (4.76)24.3611
2020's1 (1.59)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.21 (24.57)
Research Supply Index4.25 (2.92)
Research Growth Index5.46 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (7.81%)5.53%
Reviews2 (3.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other57 (89.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
acetaldehyde
Acetaldehyde: A colorless, flammable liquid used in the manufacture of acetic acid, perfumes, and flavors. It is also an intermediate in the metabolism of alcohol. It has a general narcotic action and also causes irritation of mucous membranes. Large doses may cause death from respiratory paralysis.. acetaldehyde : The aldehyde formed from acetic acid by reduction of the carboxy group. It is the most abundant carcinogen in tobacco smoke.. aldehyde : A compound RC(=O)H, in which a carbonyl group is bonded to one hydrogen atom and to one R group.. acetyl group : A group, formally derived from acetic acid by dehydroxylation, which is fundamental to the biochemistry of all forms of life. When bound to coenzyme A, it is central to the metabolism of carbohydrates and fats.		1.9910aldehydecarcinogenic agent;
EC 3.5.1.4 (amidase) inhibitor;
electron acceptor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
mutagen;
oxidising agent;
Saccharomyces cerevisiae metabolite;
teratogenic agent
quinacrine
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.		1.9710acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound		antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
benzaldehyde
[no description available]		210benzaldehydesEC 3.1.1.3 (triacylglycerol lipase) inhibitor;
EC 3.5.5.1 (nitrilase) inhibitor;
flavouring agent;
fragrance;
odorant receptor agonist;
plant metabolite
1-butanol
1-Butanol: A four carbon linear hydrocarbon that has a hydroxy group at position 1.. butan-1-ol : A primary alcohol that is butane in which a hydrogen of one of the methyl groups is substituted by a hydroxy group. It it produced in small amounts in humans by the gut microbes.		1.9810alkyl alcohol;
primary alcohol;
short-chain primary fatty alcohol		human metabolite;
mouse metabolite;
protic solvent
propionaldehyde
propionaldehyde: may cause respiratory irritation; RN given refers to parent cpd; structure. propanal : An aldehyde that consists of ethane bearing a formyl substituent. The parent of the class of propanals.		1.9910alpha-CH2-containing aldehyde;
propanals		Escherichia coli metabolite
formaldehyde
paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy		2.110aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
1-propanol
1-Propanol: A colorless liquid made by oxidation of aliphatic hydrocarbons that is used as a solvent and chemical intermediate.. propan-1-ol : The parent member of the class of propan-1-ols that is propane in which a hydrogen of one of the methyl groups is replaced by a hydroxy group.		1.9910propan-1-ols;
short-chain primary fatty alcohol		metabolite;
protic solvent
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		210isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
4,5,6,7-tetrabromo-2-azabenzimidazole
4,5,6,7-tetrabromobenzotriazole: a CK2 kinase inhibitor		3.4110
acridone
acridone : A member of the class of acridines that is 9,10-dihydroacridine substituted by an oxo group at position 9.		2.3920acridines;
cyclic ketone
amsacrine
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.		4.38210acridines;
aromatic ether;
sulfonamide		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		1.9910aromatic ether;
nitrile;
polyether;
tertiary amino compound
cimetidine
Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.		1.9810aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
diazepam
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.		1.98101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		3.5320nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
hydralazine
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.		2.0710azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines		antihypertensive agent;
vasodilator agent
metyrapone
Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.. metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.		1.9810aromatic ketoneantimetabolite;
diagnostic agent;
EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
midazolam
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.		2.0710imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
mitoxantrone
Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.		2.0110dihydroxyanthraquinoneanalgesic;
antineoplastic agent
entinostat
[no description available]		3.4110benzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
o(6)-benzylguanine
O(6)-benzylguanine: a suicide inhibitor of O(6)-methylguanine-DNA methyltransferase activity		2.0710
proadifen
Proadifen: An inhibitor of drug metabolism and CYTOCHROME P-450 ENZYME SYSTEM activity.		2.3820diarylmethane
propranolol
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.		2.0710naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
imatinib
[no description available]		3.4110aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines		antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
vorinostat
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).		3.6620dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
temozolomide
[no description available]		3.1110imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
zaleplon
zaleplon: an azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; a hypnotic with less marked effect on psychomotor functions compared to lorazepam. zaleplon : A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position.		2.0710nitrile;
pyrazolopyrimidine		anticonvulsant;
anxiolytic drug;
central nervous system depressant;
sedative
thymidine
[no description available]		1.9810pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
uridine
[no description available]		1.9810uridinesdrug metabolite;
fundamental metabolite;
human metabolite
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		3.4110alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
tromethamine
Tromethamine: An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424)		1.9910primary amino compound;
triol		buffer
aminacrine
Aminacrine: A highly fluorescent anti-infective dye used clinically as a topical antiseptic and experimentally as a mutagen, due to its interaction with DNA. It is also used as an intracellular pH indicator.. 9-aminoacridine : An aminoacridine that is acridine in which the hydrogen at position 9 is replaced by an amino group. A fluorescent dyd and topical antiseptic agent, it is used (usually as the hydrochloride salt) in eye drops for the treatment of superficial eye infections.		2.3820aminoacridines;
primary amino compound		acid-base indicator;
antiinfective agent;
antiseptic drug;
fluorescent dye;
MALDI matrix material;
mutagen
proflavine
Proflavine: Topical antiseptic used mainly in wound dressings.. 3,6-diaminoacridine : An aminoacridine that is acridine that is substituted by amino groups at positions 3 and 6. A slow-acting bacteriostat that is effective against many Gram-positive bacteria (but ineffective against spores), its salts were formerly used for treatment of burns and infected wounds.		1.9810aminoacridinesantibacterial agent;
antiseptic drug;
carcinogenic agent;
chromophore;
intercalator
xanthenes
Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.		1.9910xanthene
acridines
Acridines: Compounds that include the structure of acridine.. acridine : A polycyclic heteroarene that is anthracene in which one of the central CH groups is replaced by a nitrogen atom.		9.1505acridines;
mancude organic heterotricyclic parent;
polycyclic heteroarene		genotoxin
c 137
C 137: RN given refers to parent cpd		210
9-anilinoacridine
[no description available]		1.9810
nitracrine
Nitracrine: Acridine antineoplastic agent used in mammary and ovarian tumors. It inhibits RNA synthesis.		2.420acridines
buthionine sulfoximine
Buthionine Sulfoximine: A synthetic amino acid that depletes glutathione by irreversibly inhibiting gamma-glutamylcysteine synthetase. Inhibition of this enzyme is a critical step in glutathione biosynthesis. It has been shown to inhibit the proliferative response in human T-lymphocytes and inhibit macrophage activation. (J Biol Chem 1995;270(33):1945-7). 2-amino-4-(S-butylsulfonimidoyl)butanoic acid : A non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group carries an oxo, imino and butyl groups.. S-butyl-DL-homocysteine (S,R)-sulfoximine : A sulfoximide that is the sulfoximine derivative of an analogue of DL-methionine in which the S-methyl group is replaced by S-butyl.		1.9910diastereoisomeric mixture;
homocysteines;
non-proteinogenic alpha-amino acid;
sulfoximide		EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor;
ferroptosis inducer
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		2.9140delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
daunorubicin
Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.		2.4120aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite
razoxane
Razoxane: An antimitotic agent with immunosuppressive properties.		1.9910N-alkylpiperazine
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.3920taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
etoposide
[no description available]		3.150beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
idarubicin
Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.		1.9910anthracycline antibiotic;
deoxy hexoside;
monosaccharide derivative
irinotecan
[no description available]		2.0110carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
potassium phosphate
potassium phosphate: used in dental materials and to treat hypophosphatemia; RN given refers to cpd with unspecified MF. tripotassium phosphate : An inorganic potassium salt that is the tripotassium salt of phosphoric acid.		1.9910inorganic phosphate salt;
inorganic potassium salt
bendamustine
[no description available]		3.4110benzimidazoles
intoplicine
intoplicine: structure in first source		210pyridoindole
carbazeran
carbazeran: structure given in first source		2.0710
sn 38
SN-38 : A member of the class of pyranoindolizinoquinolines that is (4S)-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-dione bearing two additional ethyl substituents at positions 4 and 11 as well as two additional hydroxy substituents at positions 4 and 9. It is the active metabolite of irinotecan and is ~1000 times more active than irinotecan itself.		210delta-lactone;
phenols;
pyranoindolizinoquinoline;
tertiary alcohol		antineoplastic agent;
apoptosis inducer;
drug metabolite;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
asulacrine
asulacrine: derivative of amsacrine; structure given in first source		2.6630acridines
vadimezan
vadimezan : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 5,6-dimethyl-9-oxoxanthen-4-yl group.		1.9910monocarboxylic acid;
xanthones		antineoplastic agent
n-((2-dimethylamino)ethyl)-9-aminoacridine-4-carboxamide
N-((2-dimethylamino)ethyl)-9-aminoacridine-4-carboxamide: RN given refers to parent cpd; structure given in first source		2.940
pixantrone
pixantrone: an immunosuppressant; structure given in first source		2.110isoquinolines
levofloxacin
Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.		3.41109-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
erlotinib
[no description available]		3.4110aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound		antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor
lapatinib
[no description available]		3.4110furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
sorafenib
[no description available]		3.4110(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
mitonafide
[no description available]		2.0410
trichostatin a
trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES		3.4110antibiotic antifungal agent;
hydroxamic acid;
trichostatin		bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector
aphidicolin
Aphidicolin: An antiviral antibiotic produced by Cephalosporium aphidicola and other fungi. It inhibits the growth of eukaryotic cells and certain animal viruses by selectively inhibiting the cellular replication of DNA polymerase II or the viral-induced DNA polymerases. The drug may be useful for controlling excessive cell proliferation in patients with cancer, psoriasis or other dermatitis with little or no adverse effect upon non-multiplying cells.. aphidicolin : A tetracyclic diterpenoid that has an tetradecahydro-8,11a-methanocyclohepta[a]naphthalene skeleton with two hydroxymethyl substituents at positions 4 and 9, two methyl substituents at positions 4 and 11b and two hydroxy substituents at positions 3 and 9. An antibiotic with antiviral and antimitotical properties. Aphidicolin is a reversible inhibitor of eukaryotic nuclear DNA replication.		1.9810tetracyclic diterpenoidantimicrobial agent;
antimitotic;
antineoplastic agent;
antiviral drug;
apoptosis inducer;
Aspergillus metabolite;
DNA synthesis inhibitor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
fungal metabolite
methimazole
Methimazole: A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.. methimazole : A member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen.		2.38201,3-dihydroimidazole-2-thionesantithyroid drug
dasatinib
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).		3.41101,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
zd 6474
CH 331: structure in first source		3.4110aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine		antineoplastic agent;
tyrosine kinase inhibitor
cholecalciferol
Cholecalciferol: Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24.. calciol : A hydroxy seco-steroid that is (5Z,7E)-9,10-secocholesta-5,7,10(19)-triene in which the pro-S hydrogen at position 3 has been replaced by a hydroxy group. It is the inactive form of vitamin D3, being hydroxylated in the liver to calcidiol (25-hydroxyvitamin D3), which is then further hydroxylated in the kidney to give calcitriol (1,25-dihydroxyvitamin D3), the active hormone.		3.4110D3 vitamins;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
steroid hormone		geroprotector;
human metabolite
naloxone
Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.		2.0710morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
casein kinase ii
Casein Kinase II: A ubiquitous casein kinase that is comprised of two distinct catalytic subunits and dimeric regulatory subunit. Casein kinase II has been shown to phosphorylate a large number of substrates, many of which are proteins involved in the regulation of gene expression.		3.4110
dextromethorphan
Dextromethorphan: Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.. dextromethorphan : A 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough.		2.07106-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthreneantitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic
zoniporide
zoniporide: inhibits sodium-hydrogen exchanger isoform-1 (NHE-1)		2.0710
aq4n
AQ4N: structure given in first source		1.9910
chidamide
[no description available]		3.4110benzamides
nad
NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.		2.3920organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
gdc 0941
pictrelisib : A sulfonamide composed of indazole, morpholine, and methylsulfonyl-substituted piperazine rings bound to a thienopyrimidine ring.		3.4110indazoles;
morpholines;
piperazines;
sulfonamide;
thienopyrimidine		EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
cudc 101
7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide: a histone deacetylase inhibitor; structure in first source		3.4110
abemaciclib
[no description available]		3.4110
acy-1215
ricolinostat: an HDAC6 inhibitor; structure in first source		3.4110pyrimidinecarboxylic acid
osimertinib
osimertinib: an EGFR tyrosine kinase inhibitor. osimertinib : A member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. Used (as the mesylate salt) for treatment of EGFR T790M mutation positive non-small cell lung cancer.		3.4110acrylamides;
aminopyrimidine;
biaryl;
indoles;
monomethoxybenzene;
secondary amino compound;
secondary carboxamide;
substituted aniline;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
dacarbazine
(E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.		3.1110dacarbazine
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		03.3770
Experimental Leukemia
[description not available]		02.3720
Leukemia L 1210
[description not available]		02.3720
Cancer of Lung
[description not available]		03.4980
Lung Neoplasms
Tumors or cancer of the LUNG.		03.4980
Cancer of Colon
[description not available]		03.150
Leucocythaemia
[description not available]		03.0850
Colonic Neoplasms
Tumors or cancer of the COLON.		03.150
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		03.0850
Experimental Neoplasms
[description not available]		02.420
B16 Melanoma
[description not available]		02.0410
Cancer of Prostate
[description not available]		02.110
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.110
Benign Neoplasms
[description not available]		06.0265
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		06.0265
Adenocarcinoma, Basal Cell
[description not available]		02.3920
Malignant Melanoma
[description not available]		02.6830
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.3920
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		02.6830
Experimental Mammary Neoplasms
[description not available]		02.420
Carcinoma, Non-Small Cell Lung
[description not available]		0210
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		0210
Craniofacial Pain
[description not available]		03.3811
Facial Pain
Pain in the facial region including orofacial pain and craniofacial pain. Associated conditions include local inflammatory and neoplastic disorders and neuralgic syndromes involving the trigeminal, facial, and glossopharyngeal nerves. Conditions which feature recurrent or persistent facial pain as the primary manifestation of disease are referred to as FACIAL PAIN SYNDROMES.		03.3811
Carcinoma, Lewis Lung
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.		02.420
Glial Cell Tumors
[description not available]		0210
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		0210
Anesthesia
A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.		01.9810
Chromosome-Defective Micronuclei
[description not available]		01.9710